AMG 579 is a selective positive allosteric modulator (PAM) of the M1 muscarinic acetylcholine receptor, primarily researched for its therapeutic potential in neuroscience, particularly for treating cognitive deficits in Alzheimer's disease and schizophrenia. By enhancing M1 receptor signaling, it modulates cholinergic pathways in the brain to improve memory, attention, and other cognitive functions without the adverse effects associated with direct agonists. This positions it as a promising candidate for central nervous system disorders involving cholinergic dysfunction, with ongoing studies exploring its broader applications in neurodegenerative and psychiatric conditions.